[Inflammatory myofibroblastic tumour of the tonsil: case report and literature review].

Acta Otorrinolaringol Esp

Consultorio de Anatomía Patológica y Patología Pediátrica, Veracruz, México.

Published: September 2012

Inflammatory myofibroblastic tumour (inflammatory pseudotumor) is an idiopathic lesion, rare in the head and neck, of unknown aetiology. It is primarily a soft tissue, lung and orbital condition. In the world literature, only two cases with tonsillar disease have been found. We report a case of a 10-year-old girl admitted to our hospital with clinical complaints of pain in the neck region, cough with vomiting, dyspnoea and dyslexia. Clinical examination revealed halitosis and a neoformation dependent on the left tonsil. Bilateral tonsillectomy was performed.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.otorri.2010.11.011DOI Listing

Publication Analysis

Top Keywords

myofibroblastic tumour
8
[inflammatory myofibroblastic
4
tumour tonsil
4
tonsil case
4
case report
4
report literature
4
literature review]
4
review] inflammatory
4
inflammatory myofibroblastic
4
tumour inflammatory
4

Similar Publications

Desmoid-type fibromatosis (DTF) is a locally invasive tumor composed of myofibroblast-like cells and collagen; it does not metastasize but can cause significant local morbidity. Most sporadic cases are associated with mutations in the CTNNB1 gene, which encodes beta-catenin. Various treatments have been used with differing efficacy and toxicity profiles.

View Article and Find Full Text PDF

Eight patients with inflammatory myofibroblastic tumor treated with rigid bronchoscopy.

BMC Pulm Med

January 2025

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.

Background: Pulmonary inflammatory myofibroblastic tumor (IMT) accounts for 0.04-0.7% of all lung tumors, and endobronchial IMT accounts for only 10% of all pulmonary IMTs.

View Article and Find Full Text PDF

Low-grade myofibroblastic sarcoma is an uncommon malignancy that can be difficult to identify and for which there is no unified treatment protocol. We report herein a case of an 81-year-old male who presented with a giant irregular breast mass and was diagnosed with low-grade myofibroblastic sarcoma. In this study we summarise the clinicopathological features of 13 reported cases of myofibroblastic sarcoma arising in the breast, present the diagnostic process and treatment procedure of our case, and discuss the differential diagnosis from other similar diseases, to provide constructive information and promote deep understanding of myofibroblastic sarcoma in the future.

View Article and Find Full Text PDF

Significantly Elevated FDG Activity in Esophageal Inflammatory Myofibroblastic Tumor of a Pediatric Patient.

Clin Nucl Med

January 2025

From the Department of Nuclear Medicine (PET-CT Center), National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

A 13-year-old girl presented with dysphagia underwent contrast-enhanced CT and endoscopy. The CT revealed cervical esophageal wall thickening with heterogeneous enhancement. Microscopic examination of the biopsy specimen suggested a possible mesenchymal tumor.

View Article and Find Full Text PDF

Desmoid fibromatosis (DF) is a rare low-grade benign myofibroblastic neoplasm that originates from fascia and muscle striae. For giant chest wall DF, surgical resection offer a radical form of treatment and the causing defects usually need repair and reconstruction, which can restore the structural integrity and rigidity of the thoracic cage. The past decade witnessed rapid advances in the application of various prosthetic material in thoracic surgery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!